These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19731466)

  • 1. Clinical roundtable monograph. Combination therapies for MDS.
    Scott BL
    Clin Adv Hematol Oncol; 2009 Jul; 7(7):S13-5. PubMed ID: 19731466
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of MDS: something old, something new, something borrowed..
    Sekeres MA
    Hematology Am Soc Hematol Educ Program; 2009; ():656-63. PubMed ID: 20008251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug evaluation: AMG-531 for the treatment of thrombocytopenias.
    Rice L
    Curr Opin Investig Drugs; 2006 Sep; 7(9):834-41. PubMed ID: 17002262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [MDS].
    Miyazaki Y
    Rinsho Ketsueki; 2012 Jan; 53(1):51-8. PubMed ID: 22374525
    [No Abstract]   [Full Text] [Related]  

  • 5. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
    Nichol JL
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
    Scott BL; Ramakrishnan A; Storer B; Becker PS; Petersdorf S; Estey EH; Deeg HJ
    Br J Haematol; 2010 Mar; 148(6):944-7. PubMed ID: 20064151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Supportive therapy for myelodysplastic syndrome (MDS). Indispensable pillar in the multimodal treatment concept].
    Göbel A; Lubrich B
    Pharm Unserer Zeit; 2010 May; 39(3):228-33. PubMed ID: 20425777
    [No Abstract]   [Full Text] [Related]  

  • 8. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel thrombopoietic agents: preliminary activity, potential benefit.
    Bussel JB
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):63-84. PubMed ID: 17550056
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of thrombopoietins in the treatment of ITP.
    Kuter DJ
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):464-6. PubMed ID: 16167023
    [No Abstract]   [Full Text] [Related]  

  • 14. [Novel therapeutic agents for myelodysplastic syndrome].
    Ishikawa T
    Rinsho Ketsueki; 2009 Oct; 50(10):1553-9. PubMed ID: 19915366
    [No Abstract]   [Full Text] [Related]  

  • 15. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome.
    Rosenfeld C; Bedell C
    Leuk Res; 2002 Aug; 26(8):721-4. PubMed ID: 12191566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future management options for myelodysplastic syndromes.
    Bryan J; Jabbour E; Prescott H; Garcia-Manero G; Issa JP; Kantarjian H
    Drugs; 2010 Jul; 70(11):1381-94. PubMed ID: 20614946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epigenetic therapy in myelodysplastic syndromes].
    Maki K; Mitani K
    Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
    Platzbecker U; Germing U
    Leukemia; 2013 Sep; 27(9):1813-9. PubMed ID: 23644421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
    Voso MT; Santini V; Finelli C; Musto P; Pogliani E; Angelucci E; Fioritoni G; Alimena G; Maurillo L; Cortelezzi A; Buccisano F; Gobbi M; Borin L; Di Tucci A; Zini G; Petti MC; Martinelli G; Fabiani E; Fazi P; Vignetti M; Piciocchi A; Liso V; Amadori S; Leone G
    Clin Cancer Res; 2009 Aug; 15(15):5002-7. PubMed ID: 19638460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines.
    Greenberg P
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii41-2. PubMed ID: 11890651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.